{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-034076","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.114474+00:00","generated_at":"2026-06-07T14:40:12.924953+00:00","sec_items":[],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cassava Sciences expands board to 9 with three new directors","bullets":["Appointed Dr. Claude Nicaise, Pierre Gravier, and Robert Anderson, Jr. effective Dec 6, 2023.","Board expanded from 6 to 9 members; Anderson (Class I), Nicaise and Gravier (Class II).","Nicaise led regulatory/clinical roles resulting in 14 drug approvals; Gravier is CFO of PTC Therapeutics.","Anderson is former FBI Executive Assistant Director and cybersecurity expert.","No committees assigned; none have material interests in reportable transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-034076","json":"https://secwatch.observer/filing/0001437749-23-034076.json","markdown":"https://secwatch.observer/filing/0001437749-23-034076.md","text":"https://secwatch.observer/filing/0001437749-23-034076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000143774923034076/0001437749-23-034076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000143774923034076/sava20231208c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:40:12.924953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}